SCHEMBL3520717

SCHEMBL3520717

Cc1ccc(C(=O)O)cc1-n1c(C)nc(OCc2ccc(F)cc2F)c(Cl)c1=O

nearest known ligand 0.57

Predicted protein targets (top 8)

geneUniProtsupporting neighboursconfidence
MAPK14 Q16539 17/20 0.57
MAPK11 Q15759 4/20 0.57
PTGER1 P34995 2/20 0.51
ROCK2 O75116 1/20 0.51
MAPK12 P53778 1/20 0.51
STRADA Q7RTN6 1/20 0.51
MAPK1 P28482 1/20 0.45
MAPKAPK5 Q8IW41 1/20 0.45

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL3521845 0.94 PTGER1 (0.59) MAPK14MAPK11PTGER1
SCHEMBL3519366 0.92 MAPK14 (0.63) MAPK14MAPK11ROCK2MAPK12STRADA
SCHEMBL3522142 0.91 MAPK14 (0.59) MAPK14MAPK11ROCK2MAPK12STRADA
SCHEMBL14989457 0.90 MAPK14 (0.55) MAPK14MAPK11ROCK2MAPK12STRADA
SCHEMBL3524504 0.90 MAPK14 (0.64) MAPK14MAPK11ROCK2MAPK12STRADA
SCHEMBL3520783 0.90 MAPK14 (0.60) MAPK14MAPK11ROCK2MAPK12STRADA
SCHEMBL5322727 0.89 MAPK14 (0.55) MAPK14MAPK11PTGER1ROCK2MAPK12
SCHEMBL9906468 0.89 MAPK14 (0.54) MAPK14MAPK11PTGER1ROCK2MAPK12
SCHEMBL29962605 0.88 MAPK14 (0.55) MAPK14MAPK11ROCK2MAPK12STRADA
SCHEMBL14990060 0.88 MAPK14 (0.55) MAPK14MAPK11ROCK2MAPK12STRADA

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 23 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-9056110-B2 Substituted pyrimidinone-phenyl-pyrimidinyl compounds CONFLUENCE LIFE SCIENCES, INC. (US) 2015-06-16 US disclosed
US-9056110-B2 Substituted pyrimidinone-phenyl-pyrimidinyl compounds CONFLUENCE LIFE SCIENCES, INC. (US) 2015-06-16 US disclosed
US-9056110-B2 Substituted pyrimidinone-phenyl-pyrimidinyl compounds CONFLUENCE LIFE SCIENCES, INC. (US) 2015-06-16 US disclosed
WO-2013086208-A1 SUBSTITUTED PYRIMIDINONE-PHENYL-PYRIMIDINYL COMPOUNDS CONFLUENCE LIFE SCIENCES, INC. (US) 2013-06-13 WO disclosed
WO-2013086208-A1 SUBSTITUTED PYRIMIDINONE-PHENYL-PYRIMIDINYL COMPOUNDS CONFLUENCE LIFE SCIENCES, INC. (US) 2013-06-13 WO disclosed
US-20130143906-A1 SUBSTITUTED PYRIMIDINONE-PHENYL-PYRIMIDINYL COMPOUNDS CONFLUENCE LIFE SCIENCES, INC. (US) 2013-06-06 US disclosed
US-20130143906-A1 SUBSTITUTED PYRIMIDINONE-PHENYL-PYRIMIDINYL COMPOUNDS CONFLUENCE LIFE SCIENCES, INC. (US) 2013-06-06 US disclosed
US-20130143906-A1 SUBSTITUTED PYRIMIDINONE-PHENYL-PYRIMIDINYL COMPOUNDS CONFLUENCE LIFE SCIENCES, INC. (US) 2013-06-06 US disclosed
US-7795271-B2 Substituted pyrimidinones PHARMACIA CORPORATION (US) 2010-09-14 US disclosed
US-7795271-B2 Substituted pyrimidinones PHARMACIA CORPORATION (US) 2010-09-14 US disclosed
US-20090306108-A1 SUBSTITUTED PYRIMIDINONES PFIZER INC 2009-12-10 US disclosed
US-20070167621-A1 SUBSTITUTED PYRIMIDINONES PHARMACIA CORPORATION (US) 2007-07-19 US disclosed
US-20070167621-A1 SUBSTITUTED PYRIMIDINONES PHARMACIA CORPORATION (US) 2007-07-19 US disclosed
US-20070167621-A1 SUBSTITUTED PYRIMIDINONES PHARMACIA CORPORATION (US) 2007-07-19 US disclosed
US-7183287-B2 Substituted pyrimidinones PHARMACIA CORPORATION (US) 2007-02-27 US disclosed
US-7183287-B2 Substituted pyrimidinones PHARMACIA CORPORATION (US) 2007-02-27 US disclosed
US-7183287-B2 Substituted pyrimidinones PHARMACIA CORPORATION (US) 2007-02-27 US disclosed
EP-1753731-A2 PYRIMIDIN-4-ONE DERIVATIVES AND THEIR USE AS P38 KINASE MODULATORS Pharmacia Corporation (US) 2007-02-21 EP disclosed
US-20040242608-A1 Substituted pyrimidinones PHARMACIA LLC 2004-12-02 US disclosed
WO-2004087677-A2 PYRIMIDIN-4-ONE DERIVATIVES AND THEIR USE AS P38 KINASE MODULATORS PHARMACIA CORPORATION (US) 2004-10-14 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20130143906-A1 SUBSTITUTED PYRIMIDINONE-PHENYL-PYRIMIDINYL COMPOUNDS MAP3K8, MAP3K1, MAP3K2 MAPK14 56/4885MAPK11 97/4885PTGER1 223/4885
US-20090306108-A1 SUBSTITUTED PYRIMIDINONES MAPK1, MAP3K8, MAP3K7 MAPK14 38/4885MAPK11 43/4885PTGER1 245/4885
US-20040242608-A1 Substituted pyrimidinones MAPK1, MAPK7, MAP3K8 MAPK14 29/4885MAPK11 48/4885PTGER1 215/4885
US-20070167621-A1 SUBSTITUTED PYRIMIDINONES MAPK1, MAP3K8, MAP3K7 MAPK14 38/4885MAPK11 43/4885PTGER1 245/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.